|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Influence of agr on fibrinogen binding in Staphylococcus aureus Newman显示文摘 | Christiane W Damien M Timothy J | 1996 | Infect Immun1996，64，8： | 1 |
| 2 | Transparent conducting Nnc oxide thin films doped with aluminum and molybdenum显示文摘 | JOEL N D TIMOTHY A G DAVID M W TERESA M B MATTHEW Y BOBBY T TIMOTHY J C | 2007 | Journal V-acuum Society Technology2007，25，4： | 1 |
| 3 | Experimental studies in the LENS supersonic and hypersonic tunnels for hypervelocity vehicle performance and code validation 显示文摘 | Michael S H Timothy P W Matthew M | 2008 | AIAA2008，2505，： | 1 |
| 4 | Risk measures in strategic management research:auld lang syne? 显示文摘 | Collin James M | 1999 | Strategic Management Journal1999，20，2： | 1 |
| 5 | ABC of intensive care organ dysfunction显示文摘 | TIMOTHY W E SMITHIES M | 1999 | Br Med J1999，318，： | 1 |
| 6 | Treatment of heart failure guided by plasma aminoterminal brain na- triuretic peptide( N-BNP ) concentrations 显示文摘 | Richard W Troughton Christopher M Frampton Timothy G Yandle | 2000 | The Lancet2000，355，9210： | 1 |
| 7 | Oat and rye tolerance to mesosulfuron and tribenuron显示文摘 | Andrew W M Culpepper A S Timothy L G | 2007 | Weed Tech- nology2007，214，： | 1 |
| 8 | Variant of scn5asodium channel implicated in risk of cardiac arrhythmia显示文摘 | SPLAWSKI I TIMOTHY K W TATEYAMA M | 2002 | Science2002，297，： | 1 |
| 9 | A molecular basis for cardiac arrhythmia:HERG mutations cause long QT syndrome显示文摘 | Curran M E Splawski I Timothy K W | 1995 | Cell1995，80，： | 1 |
| 10 | Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia显示文摘 | SPLAWSKI I TIMOTHY K W TATEYAMA M | 2002 | Science2002，297，5585： | 1 |
| 11 | Efficacy of difloxacin in calves experimentally infected with Mannheimia haemolytica显示文摘 | Timothy W J Olchowy D V M phD | 2000 | American Journal of Veterinary Research2000，61，6： | 1 |
| 12 | MicroRNA-181b regulates NF-[kappa]B-mediated vascular inflammation显示文摘 | Sun Xinghui Icli Basak Wara Akm Khyrul Belkin Nathan He Shaolin Kobzik Lester Hunninghake Gary M Vera Miguel Pinilla Blackwell Timothy S Baron Rebecca M Feinberg Mark W | 2012 | EN2012，，： | 1 |
| 13 | Major histocompatibility complex differentition in Sacramento River chinook salmon显示文摘 | Karen M P Hedrick F W | 1999 | Genetics1999，151，： | 1 |
| 14 | Stategic risk:an ordinal approach 显示文摘 | JAMES M C TIMOTHY W R | 1992 | Management Science1992，，12： | 1 |
| 15 | A Randomized Trial of Direct Mailing of Fecal Occult Blood Tests To Increase Colorectal Cancer Screening显示文摘 | Timothy R Church M Mark W | 2004 | JNCI2004，96，10： | 1 |
| 16 | Tumor Necrosis Factor α Is Toxic to Embryonic Mesencephalic Dopamine Neurons显示文摘 | Susan O McGuire Zao Dung Ling Jack W Lipton Caryl E Sortwell Timothy J Collier Paul M Carvey | 2001 | Experimental Neurology2001，，2： | 1 |
| 17 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 18 | Early versus deferred androgen suppression in the treatment of advanced prostatic cancer显示文摘 | TIMOTHY W BIJAY N RODERICK M | 2002 | Cochrane Database Syst Rev2002，，00： | 1 |
| 19 | Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas显示文摘 | Michelle A Anderson Steven Carpenter Norman W Thompson Timothy T Nostrant Grace H Elta James M Scheiman | 2000 | The American Journal of Gastroenterology2000，，9： | 1 |
| 20 | Dynamics of transversely vibrating beams using four engineering theories 显示文摘 | SEON M H HAYM B TIMOTHY W | 1999 | J Sound Vibr1999，225，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员